We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: A diagnostic test.
- Authors
Kishi, Taro; Nakamura, Hiroshi; Iwata, Nakao
- Abstract
Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial. A recent 6-week, double-blind, randomized, placebo-controlled trial on lurasidone for acute schizophrenia in Japan1 demonstrated that lurasidone (LUR) 40 mg/day (LUR40) improved Positive and Negative Syndrome Scale (PANSS)2 total score (PANSS-T) while being well-tolerated.
- Subjects
JAPAN; SCHIZOPHRENIA; GRANTS in aid (Public finance); CLINICAL trials
- Publication
Psychiatry & Clinical Neurosciences, 2022, Vol 76, Issue 8, p401
- ISSN
1323-1316
- Publication type
Article
- DOI
10.1111/pcn.13377